Beatrice Borelli

6PUBLICATIONS
59CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 20, 2026
Reply to: From Thresholds to Tumor Sidedness: Reframing Human Epidermal Growth Factor Receptor 2 in Colorectal Cancer.

Marco Maria Germani, Beatrice Borelli, Chiara Cremolini

|Jan 08, 2026
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.

Veronica Conca, Daniele Rossini, Carlotta Antoniotti

|Nov 18, 2025
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.

Arndt Stahler, Dominik Paul Modest, Sebastian Stintzing

|Sep 04, 2025
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials.

Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto

|Nov 25, 2023
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies.

Valentina Fanotto, Daniele Rossini, Mariaelena Casagrande

|Jul 01, 2022
Pattern of recurrence and survival after D2 right colectomy for cancer: is there place for a routine more extended lymphadenectomy?

Matteo Palmeri, Andrea Peri, Valentina Pucci

Pageof 1

Frequent Collaborators

5 joint publications

Chiara Cremolini

3 joint publications

Gianluca Masi

2 joint publications

Veronica Conca

2 joint publications

Filippo Pietrantonio